Technological innovations for the diagnosis of Acute Myocardial Infarction (AMI): A medical perception

Abstract

As it is a consolidated market, technological innovations in the diagnostic medicine sector must aim not only to meet the expectations of stakeholders but also to bring an improvement in access to health and a better patient experience. A German company set out to develop a Point-Of-Care capable of detecting serum levels of high-sensitivity troponin (hs-cTNI) at very low values, in order to reduce the time to diagnosis of acute myocardial infarction. International guidelines recommend that the hs-cTNI result be available within one hour of patient sample collection, but few hospitals achieve this goal, leading to delay in clinical decision-making and consequent harm to the patient. To understand how the medical profession of cardiology understands and evaluates the importance of a technological innovation in this sector, a survey was conducted at the World Congress of Cardiology. About 32% of the interviewees do not use hs-cTNI in their service and almost half do not comply with the application of the 0h-1h protocol for diagnosis. The interviewees reported that the use of this technology would be beneficial and necessary, and added that patients with non-ischemic pathologies would also benefit from the diagnosis of myocarditis and pulmonary thromboembolism. Finally, it is concluded that, according to the perspective of the medical profession, innovation in the cardiovascular medicine sector for the diagnosis of AMI allows faster and more assertive clinical decisions, promoting a better patient experience and improving the flow within emergency services.

DOI:https://doi.org/10.56238/sevened2024.012-040